Immuron Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,544.60
3,448.00
5,599.00
6,804.20
-
Depreciation, Depletion & Amortization
684.60
3.70
3.90
4.90
-
Other Funds
-
1.60
-
-
-
Funds from Operations
1,216.20
3,449.90
3,337.30
6,268.00
-
Changes in Working Capital
1,434.40
429.00
1,821.00
763.10
-
Net Operating Cash Flow
2,650.60
3,020.90
5,158.30
7,031.10
3,527.40
Capital Expenditures
15.90
3.20
2.40
5.70
6.60
Net Investing Cash Flow
15.90
3.20
2.40
5.70
6.60
Issuance/Reduction of Debt, Net
1,485.00
-
1,872.80
1,691.60
-
Net Financing Cash Flow
7,361.60
1.60
4,335.30
8,701.10
4,373.20
Net Change in Cash
4,695.10
3,025.70
825.40
1,624.30
732.50
Free Cash Flow
2,666.50
3,024.10
5,160.80
7,036.80
3,534.00
Change in Capital Stock
8,846.60
-
2,462.60
10,392.60
4,739.00
Exchange Rate Effect
-
-
-
40.00
106.60

About Immuron

View Profile
Address
62 Lygon Street
Carlton Victoria (VIC) 3053
Australia
Employees -
Website http://www.immuron.com
Updated 07/08/2019
Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the research and development projects performed in Australia and Israel.